10118175Equality of Access: co-designing antenatal and adolescent services for health & wellbeing into public community venuesClosedCollaborative R&DInnovate UKGood Boost Wellbeing Limited (Good Boost) is a rapidly growing UK SME delivering pioneering health technology. Combined with the expertise and network access of the largest health condition charities, specialist co-design and engineering of sub-contractors and Exeter University, Good Boost's unique AI-powered technology has the potential to save the NHS £10.6m by 2030\. Through expansion of our existing digital community rehabiliation-exercise and self-management services to new populations, this project stands to generate a Year-5 post-project ROI of 26X. **Unmet Need** Antenatal and adolescent populations ('target populations') face some of the worst NHS service waiting times. The NHS's 'Core20Plus5' highlighted target populations' need for additional clinical prioritisation, particularly ethnically-diverse and low-income populations, facing the highest health inequalities. Due to health professional shortages, recent local and central government reports endorsed delivery of therapeutic and self-management services in existing community spaces. This improves access for underserved communities, improves health outcomes and reduces health inequalities. **Solution** Good Boost's innovative AI-technology has successfully delivered personalised rehabilitation-exercise and self-management services in community-venues and at-home for older adult MSK populations. This project will co-design and develop clinically effective service for antenatal and adolescent populations. The funding will build upon our initial problem understanding of target populations' and healthcare/venue stakeholders' needs. A real-world pilot will further develop, test, and validate the clinical technology, delivering industrial research critical to tailor the service to these populations' unique health needs, in turn delivering kitemarks and clinical approvals necessary for NHS-referrals and B2B sales. This will enable national rollout late 2025, meeting the urgent need. **Market Opportunity** Effective, clinically-proven technology is supported by pioneering service design. There is no AI-health product on the market delivering community-based solutions, which are the focus of government and NHS priorities. Community-delivery embedded with emotional and peer support is proven to significantly improve uptake and long-term engagement. Furthermore, no products work collaboratively with target population health condition charities to increase visibility, trust, adoption and impact. The target populations represent 2.4m people in the UK and 414m globally - a large commercial opportunity. The annual UK and global addressable/serviceable markets are £1.6B/£14.6B and £11.9M/£119.6M respectively. CAGR is 8.7%. **Objectives** This industrial research project aims to complete product and service co-design, development, piloting and research to achieve clinical approval for public rollout and commercialisation 3-6 months post-project, creating a publicly-accessible product leveraging existing community spaces, which will address the challenges highlighted in the NHS 'Core20Plus5' and reduce health inequalities.